HCA电话会确认交易所参保人几乎一比一转为无保险，2026年医保交易所逆风扩大至10亿-12亿美元

Earnings Call Insights: HCA Healthcare (HCA) Q2 2026
Management view
- “The enhanced premium tax credits expired at the end of the year and the effects, as expected, were that many people became uninsured and still needed emergency care from hospitals,” said (CEO & Director Samuel Hazen), adding, “the impact was greater than our estimates.”
- “Overall, adjusted admissions for patients who were formerly covered by the health insurance exchanges declined by 15%,” said (CEO Hazen), and “these patients migrated almost one-for-one to uninsured.”
- “Despite the payer mix shift, we were pleased with our volume growth,” said (CEO Hazen), citing that “Emergency room visits, cardiac procedures and rehab volumes helped drive these improvements,” while “the primary explanation for the decline was from reduced demand in elective surgeries.”
- “We have approved more than $7 billion in capital expenditures that should come online in the next 3 years,” said (CEO Hazen), and “we expect to use our cash flow and balance sheet strength to invest further in our business while also returning capital to our shareholders.”
- “The significant payer mix shift related to the exchanges has had an unfavorable impact on adjusted EBITDA of approximately $400 million,” said (CFO & Executive VP Mike Marks).
- “During the second quarter, the company recognized approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs,” said (CFO Marks), including “a $540 million incremental net benefit related to the recently approved Florida program from October 1, 2024, to June 30, 2026.”
Outlook
- “Our revised 2026 guidance ranges” are “revenue between $77 billion and $79.5 billion” and “diluted earnings per share between $28.70 and $30.50,” said (CFO Marks).
- “We also included revised key assumptions” of “health insurance exchanges between a negative $1 billion and $1.2 billion” and “Medicaid Supplemental Payment Program net benefit between $300 million and $500 million,” said (CFO Marks).
- “The key change in our updated estimate is driven by our evaluation that almost all of the individuals losing coverage on the exchanges are becoming uninsured versus our original assumption of 80% to 85%,” said (CFO Marks), adding, “our original assumption around declining utilization for patients that become uninsured... did not materialize.”
- “We believe the fourth quarter adjusted EBITDA growth rate compared to the prior year may be higher than for the third quarter,” said (CFO Marks), “based on our assumptions around the timing effects of exchanges, Medicaid Supplemental Payment Programs and our resiliency program.”
Financial results
- “Admissions increased 2.5% and equivalent admissions increased 2.7%,” said (CFO Marks), and “ER visits increased 3.6%.”
- “Inpatient surgeries were down 2.3%, outpatient surgeries were down 3.4%,” said (CFO Marks).
- “Capital expenditures totaled $1.2 billion in the quarter,” said (CFO Marks), and “we purchased... $2.064 billion of our outstanding shares, and we paid $171 million in dividends.”
- “Cash flow from operations was $2.3 billion in the quarter, which is a 45% decline from prior year quarter,” said (CFO Marks), attributing it “primarily due to timing differences... related to Florida's Medicaid Supplemental Payment Program as well as the prior year deferral of federal income tax payments.”
Q&A
- Benjamin Hendrix, RBC Capital Markets: “more color on your increased estimate for exchange headwinds”; (CFO Marks): “our data is telling us now that it's closer to one-for-one.”
- Albert Rice, UBS: “drill down a little bit on surgeries”; (CEO Hazen): “this year, we're down on elective 6%... we do believe that HICS demand... is a part of it.”
- Ann Hynes, Mizuho: “talk about the competitive environment... gaining market share”; (CEO Hazen): “our competitive positioning has -- is stable to growing net-net.”
- Brian Tanquilut, Jefferies: “OpEx -- other OpEx line was up”; (CFO Marks): “other operating expenses are being inflated because of the provider tax.”
- Pito Chickering, Deutsche Bank: “help bridge us how you get to your guidance”; (CFO Marks): “The first one is really volume... The second is our cost.”
- Matthew Gillmor, KeyBanc: “3 divisions represented 50% of the impact”; (CEO Hazen): “our Gulf Coast division, North Florida and South Atlantic division.”
- Benjamin Mayo, Leerink: “work requirements for 2027”; (CFO Marks): “we beefed up those teams... and we are preparing the best we can.”
- Justin Lake, Wolfe: “first quarter versus second quarter” and “volume growth by payer”; (CFO Marks): “Commercial, excluding the exchanges are up 2.4%... the total uninsured is up 15%.”
- Stephen Baxter, Wells Fargo: “attrition rates for the exchanges in 2027”; (CEO Hazen): “the loss of coverage will be less than 2026.”
- Andrew Mok, Barclays: “how many quarters worth of Florida DPP were recognized”; (CFO Marks): “that's 21 months' worth of benefit booked into the second quarter.”
- Ryan Langston, TD Cowen: “monthly cadence... and... proposed OPPS rule for '27”; (CFO Marks): “We don't comment about mid-quarter progression... we are generally pleased.”
- Scott Fidel, Goldman Sachs: “IDR claims from the No Surprises Act”; (CEO Hazen): “we have very few of our accounts go through the IDR process.”
- Kevin Fischbeck, BofA Securities: “other $450 million” in the guidance reduction; (CFO Marks): “that really reflects a bit of the moderation in our growth rates.”
Sentiment analysis
- “What’s giving you confidence” and “still not clear to me” (Hendrix; Fischbeck) reflected slightly negative analyst sentiment centered on exchange headwinds and the EBITDA bridge.
- “we are pleased,” “we believe,” and “we were pleased with our cost results” (CEO Hazen; CFO Marks) reflected slightly positive management sentiment, with repeated caveats that “The variables on the exchanges are difficult to predict.”
- Versus Q1’s tone that exchange shifts were “generally in line with our expectations” (CEO Hazen, Q1), Q2 language shifted to “the impact was greater than our estimates” (CEO Hazen, Q2).
Quarter-over-quarter comparison
- In Q1, management said, “the underlying shifts resulting from the changes in the health insurance exchanges were generally in line with our expectations,” while in Q2 management said, “these patients migrated almost one-for-one to uninsured,” and updated exchange impact assumptions to “a negative $1 billion and $1.2 billion.”
- Q1 highlighted weather/seasonal disruption (“respiratory-related admissions were down 42%”) while Q2 centered on coverage loss and mix (“enhanced premium tax credits expired”).
- Q1 guidance was “reaffirming our estimated guidance ranges for 2026,” while Q2 introduced “our revised 2026 guidance ranges” and framed them as “more in line with our long-term adjusted EBITDA growth rate target of 4% to 6%.”
Risks and concerns
- “We expected some of these patients to shift to other forms of coverage, but this did not happen,” said (CEO Hazen), and “it does put pressure on the P&L.”
- “This one-for-one migration makes up approximately 80% of our uninsured volume growth,” said (CFO Marks), and the remainder was tied to “a decrease in Medicaid conversions, mostly in Texas.”
- “We believe work requirements will have an impact,” said (CFO Marks), and mitigation included “coverage benefit support teams... embedded in all of our facilities.”
Final takeaway
Management framed Q2 around stronger-than-expected exchange-to-uninsured migration following the expiration of enhanced premium tax credits, partially offset by Medicaid supplemental payments (including Florida) and ongoing cost initiatives under the financial resiliency program. Updated full-year guidance incorporated a larger exchange-related adjusted EBITDA headwind, while management emphasized continued demand in several service lines, ongoing network capacity expansion, and a capital allocation posture that maintained sizable CapEx and share repurchases alongside dividends.
Read the full Earnings Call Transcript